Transient Myeloproliferative Syndrome

A leukemoid reaction that occurs in some newborns with Down syndrome, and rarely in non-Down syndrome infants. It may be caused by disomic homozygosity at 21q11.2 of chromosome 21. OMIM: 159595

Also Known As:

Networked: 29 relevant articles (0 outcomes, 2 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Down Syndrome (Down's Syndrome)
2.	Trisomy (Trisomies)
3.	Liver Cirrhosis (Hepatic Cirrhosis)
4.	Liver Failure
5.	Pericardial Effusion

Experts

1.	Fujiyoshi, Junko: 2 articles (01/2019 - 01/2017)
2.	Inoue, Hirosuke: 2 articles (01/2019 - 01/2017)
3.	Koga, Yuhki: 2 articles (01/2019 - 01/2017)
4.	Ochiai, Masayuki: 2 articles (01/2019 - 01/2017)
5.	Ohga, Shouichi: 2 articles (01/2019 - 01/2017)
6.	Tomizawa, Daisuke: 2 articles (04/2017 - 01/2015)
7.	Norton, A: 2 articles (01/2016 - 01/2011)
8.	Heike, Toshio: 1 article (04/2022)
9.	Ikegawa, Atsuko: 1 article (04/2022)
10.	Iwai, Atsushi: 1 article (04/2022)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Transient Myeloproliferative Syndrome:

1.	Transforming Growth Factor beta1 (TGF beta 1)IBA 04/01/1999 - "Immunohistochemical study on transforming growth factor-beta1 expression in liver fibrosis of Down's syndrome with transient abnormal myelopoiesis."
2.	DNA (Deoxyribonucleic Acid)IBA 09/01/1991 - "The parental origin of the extra chromosome 21 was studied in 20 patients with trisomy 21-associated transient myeloproliferative syndrome (TMS) using chromosomal heteromorphisms as markers; this was combined with a study of DNA polymorphisms in 5 patients. "
3.	Biomarkers (Surrogate Marker)IBA 11/01/2005 - "[Prognostic value of serum markers for liver fibrosis in transient abnormal myelopoiesis (TAM)]." 11/10/2023 - "Atypical eosinophils as a biomarker of idiopathic pericardial effusion associated with transient abnormal myelopoiesis in Down syndrome." 04/01/2004 - "A fetal case of transient abnormal myelopoiesis with severe liver failure in Down syndrome: prognostic value of serum markers."
4.	Cytarabine (Cytosar-U)FDA LinkGeneric 04/01/2023 - "Three Cases of Down Syndrome with Transient Abnormal Myelopoiesis who Underwent Liver Biopsy before Induction of Low-Dose Cytarabine." 04/01/2019 - "Exchange Transfusion and Cytarabine for Transient Abnormal Myelopoiesis in Hydrops Fetalis." 07/01/2004 - "severely affected neonates with Down syndrome and transient abnormal myelopoiesis might benefit from early cytostatic treatment with cytosine-arabinoside."
5.	Genetic Markers (Genetic Marker)IBA 10/01/1998 - "An increased disomic homozygosity of the polymorphic DNA markers in the pericentromeric region of chromosome 21q (21q11) has repeatedly been found in DS patients with ANLL-M7 and DS-specific transient abnormal myelopoiesis (TAM), compared to the majority of DS subjects without leukaemia. " 12/05/2013 - "In this issue of Blood, Roberts et al report the comprehensive screening of a large cohort of Down syndrome neonates for the transient abnormal myelopoiesis (TAM) disorder based on blood cell morphology review and screening for GATA1 mutations, the signature genetic marker of TAM."
6.	Cytostatic AgentsIBA 07/01/2004 - "severely affected neonates with Down syndrome and transient abnormal myelopoiesis might benefit from early cytostatic treatment with cytosine-arabinoside."
7.	GATA1 Transcription FactorIBA 12/09/2022 - "ML-DS originates in utero and typically presents with a self-limiting, neonatal leukemic syndrome known as transient abnormal myelopoiesis (TAM) that is caused by cooperation between trisomy 21-associated abnormalities of fetal hematopoiesis and somatic N-terminal mutations in the transcription factor GATA1. "
8.	ChemokinesIBA 01/01/2019 - "Chemokine levels predict progressive liver disease in Down syndrome patients with transient abnormal myelopoiesis."
9.	Complementary DNA (cDNA)IBA 04/01/2022 - "Sensitive detection of GATA1 mutations using complementary DNA-based analysis for transient abnormal myelopoiesis associated with the Down syndrome."
10.	CytokinesIBA 01/01/2017 - "Cytokine Profiles in Pericardial Effusion in a Down Syndrome Infant with Transient Abnormal Myelopoiesis."

Therapies and Procedures

1.	Therapeutics 01/01/2016 - "Prenatal therapy in transient abnormal myelopoiesis: a systematic review." 05/01/2022 - "Phenotypic switching to hypereosinophilia during cytoreductive therapy for transient abnormal myelopoiesis associated with Down syndrome." 09/01/2022 - "Fetal Distress and Neonatal Death After Thoracoamniotic Shunting Therapy Due to Hydrops Associated With Transient Abnormal Myelopoiesis."
2.	Drug Therapy (Chemotherapy) 01/01/2015 - "The possibility of transient abnormal myelopoiesis should be carefully considered before intensive chemotherapy is adopted. " 01/01/2023 - "Transient abnormal myelopoiesis with extramedullary involvement in a down syndrome preemie leading to an unresponsive course despite chemotherapy." 01/01/2021 - "Herein, we present a case of Down syndrome in a neonate who presented within her first week of life with life-threatening features of transient abnormal myelopoiesis requiring chemotherapy support. "
3.	Liver Transplantation 01/01/2017 - "Successful Liver Transplantation for Transient Abnormal Myelopoiesis-Associated Liver Failure."
4.	Transplantation 01/01/2018 - "Donor cell-derived transient abnormal myelopoiesis as a specific complication of umbilical cord blood transplantation."